IBF, backed by Biogen and Medison, has led an $8m series A round for small-molecule drug developer Vidac Pharma, which has an actinic keratosis treatment in phase 2 trials.
Israel Biotech Fund (IBF), a $100m venture capital fund backed by several pharmaceutical firms, has made its first investment, leading a $9m series A round for Israel-based pharmaceutical startup Vidac Pharma.
Vidac is developing small-molecule therapeutics to treat cancer and oncodermatology disease. The round, which also featured existing investors including investment firm Mivtach Shamir Holdings, will help it advance its lead candidate, an ointment treatment for actinic keratosis, through phase 2 clinical trials.
Max Herzberg, founder and chairman of Vidac,…
